|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,203.81 MXN | -0.28% |
|
+4.09% | -0.83% |
| 25/06 | Major deals involving US drugmakers and biotechs over the past decade | RE |
| 25/06 | Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +0.93% | +2.65% | +5.89% | +23.07% | +4.93% | +42.33% | +145.77% | +389.83% | +1,417.14% | 996B | |
| +1.61% | +7.22% | +4.50% | +2.06% | +18.33% | +60.81% | +47.98% | +49.13% | +111.78% | 580B | |
| +3.51% | +12.31% | +12.72% | +17.36% | +6.41% | +31.15% | +78.88% | +115.21% | +306.18% | 415B | |
| +0.99% | +5.11% | +0.24% | +7.47% | +2.16% | +29.26% | +21.27% | -2.76% | +39.13% | 326B | |
| +1.34% | +6.74% | +5.47% | +5.33% | +14.96% | +32.63% | +38.93% | +48.83% | +66.34% | 280B | |
| +1.09% | +6.90% | +1.05% | 0.00% | +1.97% | +37.22% | +23.11% | +65.45% | +248.80% | 284B | |
| +1.32% | +12.69% | +9.22% | +33.86% | -2.95% | -27.48% | -42.00% | +23.54% | +82.93% | 210B | |
| +0.40% | +4.51% | +3.98% | -0.31% | +7.79% | +25.85% | +55.35% | +45.38% | +140.91% | 190B | |
| -1.54% | -6.11% | -8.61% | -13.23% | -4.94% | -2.43% | -38.20% | -39.28% | -30.32% | 137B | |
| +1.05% | +6.32% | +10.51% | +5.54% | +5.92% | +7.71% | +38.38% | +147.08% | +486.30% | 121B | |
| +0.71% | +2.57% | -6.84% | -6.02% | +2.69% | +18.66% | -14.84% | -17.01% | -21.56% | 112B | |
| +1.72% | +3.15% | +3.58% | -3.43% | +8.71% | +42.24% | +39.17% | +12.28% | +7.07% | 102B | |
| +0.29% | +0.57% | -4.78% | -7.87% | -10.83% | -10.33% | -25.19% | -16.42% | +6.33% | 100B | |
| -0.21% | -0.44% | -0.91% | -11.05% | -8.81% | -0.87% | +78.98% | +70.96% | +536.14% | 76.3B | |
| -.--% | +1.73% | - | - | - | - | - | - | - | 63.66B | |
| +0.83% | +3.28% | +0.71% | -11.97% | +5.40% | +16.96% | +12.05% | +36.04% | +17.26% | 49.84B | |
| -0.42% | +3.35% | +1.23% | -7.50% | -16.00% | -5.50% | +7.84% | -26.48% | +242.54% | 48.84B | |
| +18.72% | +26.51% | +22.36% | +23.26% | +26.99% | +77.96% | -6.93% | -9.25% | -46.37% | 44.18B | |
| +0.06% | +4.31% | +1.28% | -3.79% | -7.10% | -9.18% | +6.48% | - | - | 40.39B | |
| Average | +1.91% | +4.67% | +3.42% | +2.93% | +3.09% | +20.39% | +25.95% | +52.50% | +212.39% | 219.85B | |
| Weighted average by Cap. | +1.50% | +4.45% | +4.53% | +9.35% | +5.93% | +31.20% | +57.88% | +128.94% | +455.43% |
- Stock Market
- Stocks
- GILD Stock
- GILD * Stock
- Sector Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
